Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: VHL (ImmuneEditome ID:7428)

1. Gene summary of enriched editing regions for VHL

Gene summary

Gene information	Gene symbol	VHL
	Gene ID	7428
	GeneSynonyms	HRCA1\|RCA1\|VHL1\|pVHL
	GeneCytomap	3p25.3
	GeneType	protein-coding
	GeneDescription	von Hippel-Lindau disease tumor suppressor\|elongin binding protein\|protein G7\|von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
	GeneModificationdate	20230420
	UniprotID	P40337;A0A0S2Z4K1;A0A024R2F2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr3:10143182-10144277:+	ENST00000477538.1	ENSG00000134086.7	VHL	ncRNA_intronic	Charlie16a,AluSx,AluJo,AluSc5,L2b	chr3:10143182-10144277:+.alignment
chr3:10145439-10146352:+	ENST00000477538.1	ENSG00000134086.7	VHL	ncRNA_intronic	AluY,MIRb,L1ME2	chr3:10145439-10146352:+.alignment
chr3:10150869-10152259:+	ENST00000256474.2	ENSG00000134086.7	VHL	UTR3	L1ME4a,AluSx1,AluJr,AluSx	chr3:10150869-10152259:+.alignment
chr3:10150869-10152259:+	ENST00000345392.2	ENSG00000134086.7	VHL	UTR3	L1ME4a,AluSx1,AluJr,AluSx	chr3:10150869-10152259:+.alignment

Top

2. Tumor-specific enriched editing regions for VHL

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr3:10150869-10152259:+	BRCA	EER	1.5245e-03
ENSG00000134086.7,VHL	BRCA	EAG	1.3350e-03
chr3:10150869-10152259:+	COAD	EER	1.7716e-07
ENSG00000134086.7,VHL	COAD	EAG	1.5583e-07
chr3:10150869-10152259:+	KICH	EER	3.2603e-05
ENSG00000134086.7,VHL	KICH	EAG	3.2603e-05
chr3:10150869-10152259:+	KIRC	EER	7.7401e-04
ENSG00000134086.7,VHL	KIRC	EAG	3.8072e-04
chr3:10150869-10152259:+	KIRP	EER	3.3683e-02
ENSG00000134086.7,VHL	KIRP	EAG	3.1084e-02
chr3:10150869-10152259:+	LUAD	EER	1.5042e-02
ENSG00000134086.7,VHL	LUAD	EAG	1.3870e-02
chr3:10150869-10152259:+	LUSC	EER	8.9737e-03
ENSG00000134086.7,VHL	LUSC	EAG	9.1590e-03
chr3:10150869-10152259:+	PRAD	EER	4.6750e-02
ENSG00000134086.7,VHL	PRAD	EAG	4.5720e-02
chr3:10150869-10152259:+	THCA	EER	6.2835e-04
ENSG00000134086.7,VHL	THCA	EAG	6.2248e-04
chr3:10150869-10152259:+	UCEC	EER	7.7859e-03
ENSG00000134086.7,VHL	UCEC	EAG	7.1740e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr3:10150869-10152259:+	KIRC	Path	EER	5.4655e-03	1.0306e-03	0.1474
ENSG00000134086.7,VHL	KIRC	Path	EAG	2.8194e-03	8.7308e-04	0.1494

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr3:10150869-10152259:+	DLBC	EER	1.7031e-02	1.9559e-02	6.6472e-27
ENSG00000134086.7,VHL	DLBC	EAG	1.7031e-02	1.9559e-02	6.6472e-27

Top

3. Enriched editing regions and immune related genes for VHL

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for VHL

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for VHL

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr3:10150869-10152259:+	ACC	EER	T_cells_CD4_memory_resting	1.0422e-02	0.3065
ENSG00000134086.7,VHL	ACC	EAG	T_cells_CD4_memory_resting	1.0422e-02	0.3065
chr3:10150869-10152259:+	BLCA	EER	T_cells_CD4_memory_activated	2.4382e-04	0.1822
ENSG00000134086.7,VHL	BLCA	EAG	T_cells_CD4_memory_activated	4.2889e-04	0.1750
chr3:10150869-10152259:+	BRCA	EER	Dendritic_cells_activated	1.8849e-08	0.1700
ENSG00000134086.7,VHL	BRCA	EAG	Dendritic_cells_activated	3.4454e-08	0.1668
chr3:10150869-10152259:+	CESC	EER	Monocytes	1.8493e-03	0.1793
ENSG00000134086.7,VHL	CESC	EAG	Monocytes	1.7612e-03	0.1802
chr3:10150869-10152259:+	CHOL	EER	T_cells_CD4_naive	1.5521e-07	0.7555
ENSG00000134086.7,VHL	CHOL	EAG	T_cells_CD4_naive	1.5521e-07	0.7555
chr3:10150869-10152259:+	COAD	EER	T_cells_CD4_naive	1.9987e-02	0.1426
ENSG00000134086.7,VHL	COAD	EAG	T_cells_CD4_naive	2.1832e-02	0.1406
chr3:10150869-10152259:+	DLBC	EER	T_cells_CD8	1.2827e-02	0.3604
ENSG00000134086.7,VHL	DLBC	EAG	T_cells_CD8	1.2827e-02	0.3604
chr3:10143182-10144277:+	ESCA	EER	Macrophages_M2	3.8133e-03	0.5044
chr3:10150869-10152259:+	ESCA	EER	B_cells_naive	1.4087e-03	-0.2496
ENSG00000134086.7,VHL	ESCA	EAG	B_cells_naive	9.1768e-04	-0.2588
chr3:10150869-10152259:+	GBM	EER	T_cells_regulatory_(Tregs)	4.2675e-02	0.1580
ENSG00000134086.7,VHL	GBM	EAG	T_cells_regulatory_(Tregs)	4.6627e-02	0.1551
chr3:10150869-10152259:+	HNSC	EER	B_cells_naive	2.2116e-02	-0.1036
ENSG00000134086.7,VHL	HNSC	EAG	B_cells_naive	2.2116e-02	-0.1036
chr3:10150869-10152259:+	KICH	EER	Plasma_cells	1.1377e-02	0.3247
ENSG00000134086.7,VHL	KICH	EAG	Plasma_cells	1.1377e-02	0.3247
chr3:10150869-10152259:+	KIRC	EER	B_cells_memory	7.6677e-03	0.1411
ENSG00000134086.7,VHL	KIRC	EAG	B_cells_memory	8.2112e-03	0.1399
chr3:10150869-10152259:+	LAML	EER	T_cells_CD8	6.0474e-03	0.2293
ENSG00000134086.7,VHL	LAML	EAG	T_cells_CD8	9.6115e-03	0.2166
chr3:10150869-10152259:+	LGG	EER	T_cells_CD4_naive	2.0952e-02	0.1005
ENSG00000134086.7,VHL	LGG	EAG	T_cells_CD4_naive	2.1362e-02	0.1002
chr3:10150869-10152259:+	LIHC	EER	NK_cells_activated	1.4972e-03	0.1672
ENSG00000134086.7,VHL	LIHC	EAG	NK_cells_activated	1.4972e-03	0.1672
chr3:10150869-10152259:+	LUAD	EER	T_cells_gamma_delta	7.7893e-06	0.1965
ENSG00000134086.7,VHL	LUAD	EAG	T_cells_gamma_delta	8.9095e-06	0.1953
chr3:10150869-10152259:+	LUSC	EER	Neutrophils	7.3618e-04	0.1523
ENSG00000134086.7,VHL	LUSC	EAG	Neutrophils	7.3764e-04	0.1523
chr3:10150869-10152259:+	OV	EER	T_cells_CD8	6.8375e-04	0.1976
ENSG00000134086.7,VHL	OV	EAG	T_cells_CD8	6.3138e-04	0.1989
chr3:10150869-10152259:+	PAAD	EER	Macrophages_M2	1.2885e-02	-0.1877
ENSG00000134086.7,VHL	PAAD	EAG	Macrophages_M2	1.2784e-02	-0.1879
chr3:10150869-10152259:+	PCPG	EER	T_cells_CD4_memory_resting	2.7403e-02	-0.1687
ENSG00000134086.7,VHL	PCPG	EAG	T_cells_CD4_memory_resting	2.7403e-02	-0.1687
chr3:10150869-10152259:+	PRAD	EER	Plasma_cells	9.2368e-03	0.1167
ENSG00000134086.7,VHL	PRAD	EAG	Plasma_cells	9.5088e-03	0.1162
chr3:10150869-10152259:+	READ	EER	NK_cells_activated	5.1269e-05	0.4031
ENSG00000134086.7,VHL	READ	EAG	NK_cells_activated	5.1269e-05	0.4031
chr3:10150869-10152259:+	SKCM	EER	Dendritic_cells_activated	6.2475e-06	0.2135
ENSG00000134086.7,VHL	SKCM	EAG	Dendritic_cells_activated	6.2475e-06	0.2135
chr3:10150869-10152259:+	STAD	EER	Macrophages_M2	2.0552e-02	0.1205
ENSG00000134086.7,VHL	STAD	EAG	Macrophages_M2	2.7744e-02	0.1146
chr3:10150869-10152259:+	TGCT	EER	Macrophages_M2	5.2042e-07	-0.3950
ENSG00000134086.7,VHL	TGCT	EAG	Macrophages_M2	5.2706e-07	-0.3948
chr3:10150869-10152259:+	THCA	EER	Monocytes	1.6967e-02	0.1073
ENSG00000134086.7,VHL	THCA	EAG	Monocytes	1.7148e-02	0.1071
chr3:10150869-10152259:+	THYM	EER	NK_cells_resting	1.7188e-03	0.2930
ENSG00000134086.7,VHL	THYM	EAG	NK_cells_resting	1.7188e-03	0.2930
chr3:10150869-10152259:+	UCEC	EER	Dendritic_cells_resting	6.4437e-03	-0.2064
ENSG00000134086.7,VHL	UCEC	EAG	Dendritic_cells_resting	5.1521e-03	-0.2112
chr3:10150869-10152259:+	UCS	EER	NK_cells_activated	1.0097e-03	-0.4277
ENSG00000134086.7,VHL	UCS	EAG	NK_cells_activated	9.3670e-04	-0.4302

Top

6. Enriched editing regions and immune gene sets for VHL

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000134086.7,VHL	LUAD	EAG	6.0143e-09	0.2539	1.6389e-08	0.2468	3.2071e-08	0.2418	1.3290e-02	0.1096
chr3:10150869-10152259:+	LUAD	EER	3.9391e-09	0.2569	1.3005e-08	0.2484	2.3559e-08	0.2441	8.5446e-03	0.1163

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr3:10150869-10152259:+	ACC	GSVA_HALLMARK_COMPLEMENT	EER	4.1937e-02	-0.2456
ENSG00000134086.7,VHL	ACC	GSVA_HALLMARK_COMPLEMENT	EAG	4.1937e-02	-0.2456
ENSG00000134086.7,VHL	BLCA	GSVA_HALLMARK_APICAL_JUNCTION	EAG	1.9217e-02	0.1169
chr3:10150869-10152259:+	BLCA	GSVA_HALLMARK_APICAL_JUNCTION	EER	7.3743e-03	0.1336
chr3:10150869-10152259:+	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.9057e-14	0.2246
ENSG00000134086.7,VHL	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.1443e-13	0.2207
ENSG00000134086.7,VHL	CESC	GSVA_HALLMARK_P53_PATHWAY	EAG	3.4890e-02	0.1221
chr3:10150869-10152259:+	CESC	GSVA_HALLMARK_P53_PATHWAY	EER	3.3836e-02	0.1228
ENSG00000134086.7,VHL	CHOL	GSVA_HALLMARK_MYOGENESIS	EAG	1.5097e-02	-0.4075
chr3:10150869-10152259:+	CHOL	GSVA_HALLMARK_MYOGENESIS	EER	1.5097e-02	-0.4075
chr3:10150869-10152259:+	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.4088e-04	-0.2313
ENSG00000134086.7,VHL	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	8.7968e-05	-0.2381
ENSG00000134086.7,VHL	DLBC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.4494e-03	-0.4181
chr3:10150869-10152259:+	DLBC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.4494e-03	-0.4181
ENSG00000134086.7,VHL	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	8.7118e-06	-0.3425
chr3:10150869-10152259:+	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.3810e-05	-0.3206
ENSG00000134086.7,VHL	GBM	GSVA_HALLMARK_MYOGENESIS	EAG	3.1310e-02	-0.1677
chr3:10150869-10152259:+	GBM	GSVA_HALLMARK_MYOGENESIS	EER	3.6991e-02	-0.1625
ENSG00000134086.7,VHL	HNSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	4.2888e-02	0.0917
chr3:10150869-10152259:+	HNSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.2888e-02	0.0917
chr3:10150869-10152259:+	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.1673e-05	0.2300
ENSG00000134086.7,VHL	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.4104e-05	0.2178
chr3:10150869-10152259:+	KIRP	GSVA_HALLMARK_P53_PATHWAY	EER	9.2008e-03	-0.1562
ENSG00000134086.7,VHL	KIRP	GSVA_HALLMARK_P53_PATHWAY	EAG	6.3781e-03	-0.1635
chr3:10150869-10152259:+	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.3929e-02	-0.1070
ENSG00000134086.7,VHL	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.3734e-02	-0.1072
ENSG00000134086.7,VHL	LIHC	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.5264e-04	0.1988
chr3:10150869-10152259:+	LIHC	GSVA_HALLMARK_ADIPOGENESIS	EER	1.5264e-04	0.1988
chr3:10150869-10152259:+	LUAD	GSVA_HALLMARK_DNA_REPAIR	EER	1.4933e-11	0.2930
ENSG00000134086.7,VHL	LUAD	GSVA_HALLMARK_DNA_REPAIR	EAG	2.8536e-11	0.2890
ENSG00000134086.7,VHL	LUSC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	1.3572e-02	0.1117
chr3:10150869-10152259:+	LUSC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.2440e-02	0.1131
ENSG00000134086.7,VHL	MESO	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.5463e-02	0.2467
chr3:10150869-10152259:+	MESO	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.5463e-02	0.2467
ENSG00000134086.7,VHL	OV	GSVA_HALLMARK_DNA_REPAIR	EAG	8.6484e-04	0.1939
chr3:10150869-10152259:+	OV	GSVA_HALLMARK_DNA_REPAIR	EER	9.1966e-04	0.1929
ENSG00000134086.7,VHL	PAAD	GSVA_HALLMARK_APICAL_JUNCTION	EAG	4.2723e-02	0.1534
chr3:10150869-10152259:+	PAAD	GSVA_HALLMARK_APICAL_JUNCTION	EER	4.0207e-02	0.1553
ENSG00000134086.7,VHL	PCPG	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	9.2072e-03	-0.1986
chr3:10150869-10152259:+	PCPG	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	9.2072e-03	-0.1986
ENSG00000134086.7,VHL	PRAD	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	1.2365e-02	-0.1121
chr3:10150869-10152259:+	PRAD	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	1.3434e-02	-0.1108
chr3:10150869-10152259:+	READ	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.3960e-02	-0.2178
ENSG00000134086.7,VHL	READ	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	3.3960e-02	-0.2178
ENSG00000134086.7,VHL	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	9.5305e-03	-0.1624
chr3:10150869-10152259:+	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	9.5880e-03	-0.1622
ENSG00000134086.7,VHL	SKCM	GSVA_HALLMARK_APICAL_JUNCTION	EAG	9.1961e-04	0.1574
chr3:10150869-10152259:+	SKCM	GSVA_HALLMARK_APICAL_JUNCTION	EER	9.1961e-04	0.1574
ENSG00000134086.7,VHL	STAD	GSVA_HALLMARK_HYPOXIA	EAG	6.4534e-04	0.1768
chr3:10150869-10152259:+	STAD	GSVA_HALLMARK_HYPOXIA	EER	1.1230e-04	0.1997
ENSG00000134086.7,VHL	TGCT	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	1.0601e-08	-0.4447
chr3:10150869-10152259:+	TGCT	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.0450e-08	-0.4449
ENSG00000134086.7,VHL	THCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.4623e-02	-0.0950
chr3:10150869-10152259:+	THCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.5433e-02	-0.0946
chr3:10150869-10152259:+	THYM	GSVA_HALLMARK_UV_RESPONSE_UP	EER	7.8650e-03	0.2499
ENSG00000134086.7,VHL	THYM	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	7.8650e-03	0.2499
chr3:10150869-10152259:+	UCEC	GSVA_HALLMARK_ANGIOGENESIS	EER	7.8580e-05	-0.2956
ENSG00000134086.7,VHL	UCEC	GSVA_HALLMARK_ANGIOGENESIS	EAG	8.5215e-05	-0.2934
ENSG00000134086.7,VHL	UCS	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	1.7035e-02	0.3177
chr3:10150869-10152259:+	UCS	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.6934e-02	0.3180
ENSG00000134086.7,VHL	UVM	GSVA_HALLMARK_SPERMATOGENESIS	EAG	4.8960e-02	-0.3134

Top

7. Enriched editing regions and drugs for VHL

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000134086.7,VHL	ACC	CI.1040	EAG	1.7559e-03	0.3700
chr3:10150869-10152259:+	ACC	CI.1040	EER	1.7559e-03	0.3700
ENSG00000134086.7,VHL	BLCA	CMK	EAG	7.1329e-05	-0.1970
chr3:10150869-10152259:+	BLCA	CMK	EER	2.6878e-05	-0.2080
chr3:10150869-10152259:+	BRCA	CMK	EER	6.2105e-08	-0.1639
ENSG00000134086.7,VHL	BRCA	CMK	EAG	7.4949e-08	-0.1628
ENSG00000134086.7,VHL	CESC	Gefitinib	EAG	6.4624e-03	-0.1572
chr3:10150869-10152259:+	CESC	Gefitinib	EER	5.8167e-03	-0.1591
chr3:10150869-10152259:+	CHOL	Bleomycin	EER	7.6296e-04	0.5424
ENSG00000134086.7,VHL	CHOL	Bleomycin	EAG	7.6296e-04	0.5424
ENSG00000134086.7,VHL	COAD	AZ628	EAG	3.2063e-03	0.1801
chr3:10150869-10152259:+	COAD	AZ628	EER	6.5125e-03	0.1664
ENSG00000134086.7,VHL	DLBC	GW843682X	EAG	7.7070e-04	-0.4737
chr3:10150869-10152259:+	DLBC	GW843682X	EER	7.7070e-04	-0.4737
ENSG00000134086.7,VHL	ESCA	CMK	EAG	6.9547e-04	-0.2646
chr3:10150869-10152259:+	ESCA	CMK	EER	6.6692e-04	-0.2654
ENSG00000134086.7,VHL	GBM	LFM.A13	EAG	1.2118e-02	0.1949
chr3:10150869-10152259:+	GBM	LFM.A13	EER	1.1435e-02	0.1965
chr3:10150869-10152259:+	HNSC	BAY.61.3606	EER	9.1845e-07	0.2200
ENSG00000134086.7,VHL	HNSC	BAY.61.3606	EAG	9.1845e-07	0.2200
chr3:10150869-10152259:+	KICH	DMOG	EER	1.0774e-02	0.3270
ENSG00000134086.7,VHL	KICH	DMOG	EAG	1.0774e-02	0.3270
chr3:10150869-10152259:+	KIRC	AG.014699	EER	6.4911e-03	0.1440
ENSG00000134086.7,VHL	KIRC	Embelin	EAG	3.9864e-03	0.1522
ENSG00000134086.7,VHL	LAML	BI.D1870	EAG	3.4616e-02	-0.1775
chr3:10150869-10152259:+	LAML	BI.D1870	EER	3.2053e-02	-0.1800
ENSG00000134086.7,VHL	LGG	ATRA	EAG	5.2576e-03	0.1213
chr3:10150869-10152259:+	LGG	ATRA	EER	5.1687e-03	0.1215
ENSG00000134086.7,VHL	LIHC	IPA.3	EAG	1.6116e-05	0.2261
chr3:10150869-10152259:+	LIHC	IPA.3	EER	1.6116e-05	0.2261
ENSG00000134086.7,VHL	LUAD	Gemcitabine	EAG	1.5430e-06	-0.2109
chr3:10150869-10152259:+	LUAD	Gemcitabine	EER	1.6161e-06	-0.2105
ENSG00000134086.7,VHL	LUSC	GSK269962A	EAG	3.7869e-02	-0.0940
chr3:10150869-10152259:+	LUSC	GSK269962A	EER	3.6294e-02	-0.0948
ENSG00000134086.7,VHL	MESO	Cytarabine	EAG	2.8379e-04	0.3908
chr3:10150869-10152259:+	MESO	Cytarabine	EER	2.8379e-04	0.3908
ENSG00000134086.7,VHL	OV	CHIR.99021	EAG	2.1577e-02	0.1344
chr3:10150869-10152259:+	OV	LFM.A13	EER	2.3946e-02	0.1321
ENSG00000134086.7,VHL	PCPG	Imatinib	EAG	4.1141e-03	0.2184
chr3:10150869-10152259:+	PCPG	Imatinib	EER	4.1141e-03	0.2184
ENSG00000134086.7,VHL	PRAD	DMOG	EAG	4.1288e-02	0.0916
chr3:10150869-10152259:+	PRAD	DMOG	EER	3.5565e-02	0.0943
chr3:10150869-10152259:+	READ	Gefitinib	EER	1.4374e-02	-0.2504
ENSG00000134086.7,VHL	READ	Gefitinib	EAG	1.4374e-02	-0.2504
ENSG00000134086.7,VHL	SARC	AZD.2281	EAG	1.2626e-02	-0.1563
chr3:10150869-10152259:+	SARC	AZD.2281	EER	1.2637e-02	-0.1563
chr3:10150869-10152259:+	SKCM	GNF.2	EER	5.4269e-04	-0.1642
ENSG00000134086.7,VHL	SKCM	GNF.2	EAG	5.4269e-04	-0.1642
chr3:10143182-10144277:+	STAD	AICAR	EER	4.8912e-02	0.2398
chr3:10150869-10152259:+	STAD	Bleomycin	EER	6.6142e-05	-0.2062
ENSG00000134086.7,VHL	STAD	Bleomycin	EAG	4.8776e-05	-0.2098
ENSG00000134086.7,VHL	TGCT	BMS.754807	EAG	1.1487e-06	0.3838
chr3:10150869-10152259:+	TGCT	BMS.754807	EER	1.1128e-06	0.3842
ENSG00000134086.7,VHL	THCA	ATRA	EAG	2.6409e-03	0.1350
chr3:10150869-10152259:+	THCA	ATRA	EER	2.7012e-03	0.1347
ENSG00000134086.7,VHL	THYM	AS601245	EAG	2.7006e-02	0.2090
chr3:10150869-10152259:+	THYM	AS601245	EER	2.7006e-02	0.2090
chr3:10150869-10152259:+	UCEC	GDC.0449	EER	4.0132e-09	-0.4286
ENSG00000134086.7,VHL	UCEC	GDC.0449	EAG	1.5699e-09	-0.4375
chr3:10150869-10152259:+	UCS	BIRB.0796	EER	5.1030e-04	-0.4495
ENSG00000134086.7,VHL	UCS	BIRB.0796	EAG	4.8726e-04	-0.4509
ENSG00000134086.7,VHL	UVM	BMS.509744	EAG	5.2728e-03	-0.4329

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType